Interleukin 33 in tumor microenvironment is crucial for the accumulation and function of myeloid-derived suppressor cells

OncoImmunology

Volumn 5, Issue 1, 2016, Pages

  Xiao, Peng ^a,b   Wan, Xiaopeng ^a   Cui, Bijun ^a   Liu, Yang ^a   Qiu, Chenyang ^a   Rong, Jiabing ^a   Zheng, Mingzhu ^a   Song, Yinjing ^a   Chen, Luoquan ^a   He, Jia ^a   Tan, Qinchun ^a   Wang, Xiaojia ^c   Shao, Xiying ^c   Liu, Yuhua ^d   Cao, Xuetao ^a,e   Wang, Qingqing ^a  

^a ZHEJIANG UNIVERSITY SCHOOL OF MEDICINE   (China)

^b ZHEJIANG UNIVERSITY   (China)

^c ZHEJIANG CANCER HOSPITAL   (China)

^d HANGZHOU FIRST PEOPLE'S HOSPITAL   (China)

^e INSTITUTE OF BASIC MEDICAL SCIENCES   (China)

Author keywords

Autocrine GM CSF; Interleukin 33; Myeloid derived suppressor cells; Tumor microenvironment

Indexed keywords

ARGINASE 1; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 33; INTERLEUKIN 6; MITOGEN ACTIVATED PROTEIN KINASE; STAT3 PROTEIN; TRANSFORMING GROWTH FACTOR BETA;

ADOPTIVE TRANSFER; ANIMAL CELL; ARTICLE; BONE MARROW CELL; BREAST CANCER; CANCER IMMUNOTHERAPY; CONTROLLED STUDY; DOWN REGULATION; ENZYME LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; HISTONE MODIFICATION; HUMAN; HUMAN TISSUE; IMMUNE EVASION; IMMUNOHISTOCHEMISTRY; IMMUNOSUPPRESSIVE TREATMENT; NONHUMAN; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; RNA ISOLATION; SIGNAL TRANSDUCTION; TUMOR ESCAPE; TUMOR MICROENVIRONMENT; UPREGULATION; WESTERN BLOTTING;

EID: 84954426099     PISSN: 21624011     EISSN: 2162402X     Source Type: Journal    
DOI: 10.1080/2162402X.2015.1063772     Document Type: Article

References (46)

1. Gabrilovich DI, Nagaraj S. Myeloid-derived suppressor cells as regulators of the immune system. Nat Rev Immunol 2009; 9:162-74; PMID:19197294; http://dx. doi. org/10. 1038/nri2506
2. Talmadge JE, Gabrilovich DI. History of myeloid-derived suppressor cells. Nat Rev Cancer 2013; 13:739-52; PMID:24060865; http://dx. doi. org/10. 1038/nrc3581
3. Peranzoni E, Zilio S, Marigo I, Dolcetti L, Zanovello P, Mandruzzato S, Bronte V. Myeloid-derived suppressor cell heterogeneity and subset definition. Curr Opin Immunol 2010; 22:238-44; PMID:20171075; http://dx. doi. org/10. 1016/j. coi. 2010. 01. 021
4. Ugel S, Delpozzo F, Desantis G, Papalini F, Simonato F, Sonda N, Zilio S, Bronte V. Therapeutic targeting of myeloid-derived suppressor cells. Curr Opin Pharmacol 2009; 9:470-81; PMID:19616475; http://dx. doi. org/10. 1016/j. coph. 2009. 06. 014
5. Corzo CA, Condamine T, Lu L, Cotter MJ, Youn JI, Cheng P, Cho HI, Celis E, Quiceno DG, Padhya T et al. HIF-1alpha regulates function and differentiation of myeloid-derived suppressor cells in the tumor microenvironment. J Exp Med 2010; 207:2439-53; PMID:20876310; http://dx. doi. org/10. 1084/jem. 20100587
6. Ko JS, Rayman P, Ireland J, Swaidani S, Li G, Bunting KD, Rini B, Finke JH, Cohen PA. Direct and differential suppression of myeloidderived suppressor cell subsets by sunitinib is compartmentally constrained. Cancer Res 2010; 70:3526-36; PMID:20406969; http://dx. doi. org/10. 1158/0008-5472. CAN-09-3278
7. Maenhout SK, Van Lint S, Emeagi PU, Thielemans K, Aerts JL. Enhanced suppressive capacity of tumor-infiltrating myeloid-derived suppressor cells compared with their peripheral counterparts. Int J Cancer 2014; 134:1077-90; PMID:23983191; http://dx. doi. org/ 10. 1002/ijc. 28449
8. Schmitz J, Owyang A, Oldham E, Song Y, Murphy E, McClanahan TK, Zurawski G, Moshrefi M, Qin J, Li X et al. IL-33, an interleukin-1-like cytokine that signals via the IL-1 receptor-related protein ST2 and induces T helper type 2-associated cytokines. Immunity 2005; 23:479-90; PMID:16286016; http://dx. doi. org/S1074-7613(05)00311-0
9. Mirchandani AS, Salmond RJ, Liew FY. Interleukin-33 and the function of innate lymphoid cells. Trends Immunol 2012; 33:389-96; PMID:22609147; http://dx. doi. org/10. 1016/j. it. 2012. 04. 005
10. Palmer G, Lipsky BP, Smithgall MD, Meininger D, Siu S, Talabot-Ayer D, Gabay C, Smith DE. The IL-1 receptor accessory protein (AcP) is required for IL-33 signaling and soluble AcP enhances the ability of soluble ST2 to inhibit IL-33. Cytokine 2008; 42:358-64; PMID:18450470; http://dx. doi. org/10. 1016/j. cyto. 2008. 03. 008
11. Bonilla WV, Frohlich A, Senn K, Kallert S, Fernandez M, Johnson S, Kreutzfeldt M, Hegazy AN, Schrick C, Fallon PG et al. The alarmin interleukin-33 drives protective antiviral CD8(+) T cell responses. Science 2012; 335:984-9; PMID:22323740; http://dx. doi. org/10. 1126/ science. 1215418
12. Palmer G, Gabay C. Interleukin-33 biology with potential insights into human diseases. Nat Rev Rheumatol 2011; 7:321-9; PMID:21519352; http://dx. doi. org/10. 1038/nrrheum. 2011. 53
13. Kakkar R, Hei H, Dobner S, Lee RT. Interleukin 33 as a mechanically responsive cytokine secreted by living cells. J Biol Chem 2012; 287:6941-8; PMID:22215666; http://dx. doi. org/10. 1074/jbc. M111. 298703
14. +T and NK cells. J Immunol 2015; 194:438-45; PMID:25429071; http://dx. doi. org/ 10. 4049/jimmunol. 1401344
15. Jovanovic I, Radosavljevic G, Mitrovic M, Juranic VL, McKenzie AN, Arsenijevic N, Jonjic S, Lukic ML. ST2 deletion enhances innate and acquired immunity to murine mammary carcinoma. Eur J Immunol 2011; 41:1902-12; PMID:21484786; http://dx. doi. org/10. 1002/eji. 201141417
16. Pulaski BA, Ostrand-Rosenberg S Reduction of established spontaneous mammary carcinoma metastases following immunotherapy with major histocompatibility complex class II and B7. 1 cell-based tumor vaccines. Cancer Res 1998; 58:1486-93; PMID:9537252
17. Bayne LJ, Beatty GL, Jhala N, Clark CE, Rhim AD, Stanger BZ, Vonderheide RH. Tumor-derived granulocyte-macrophage colony-stimulating factor regulates myeloid inflammation and T cell immunity in pancreatic cancer. Cancer Cell 2012; 21:822-35; PMID:22698406; http://dx. doi. org/10. 1016/j. ccr. 2012. 04. 025
18. Yang L, Huang J, Ren X, Gorska AE, Chytil A, Aakre M, Carbone DP, Matrisian LM, Richmond A, Lin PC et al. Abrogation of TGF beta signaling in mammary carcinomas recruits Gr-1+CD11b+ myeloid cells that promote metastasis. Cancer Cell 2008; 13:23-35; PMID:18167337; http://dx. doi. org/10. 1016/j. ccr. 2007. 12. 004
19. Liu Y, Lai L, Chen Q, Song Y, Xu S, Ma F, Wang X, Wang J, Yu H, Cao X et al. MicroRNA-494 is required for the accumulation and functions of tumor-expanded myeloid-derived suppressor cells via targeting of PTEN. J Immunol 2012; 188:5500-10; PMID:22544933; http://dx. doi. org/10. 4049/jimmunol. 1103505
20. Mayuzumi N, Matsushima H, Takashima A. IL-33 promotes DC development in BM culture by triggering GM-CSF production. Eur J Immunol 2009; 39:3331-42; PMID:19750479; http://dx. doi. org/ 10. 1002/eji. 200939472
21. Bunt SK, Yang L, Sinha P, Clements VK, Leips J, Ostrand-Rosenberg S. Reduced inflammation in the tumor microenvironment delays the accumulation of myeloid-derived suppressor cells and limits tumor progression. Cancer Res 2007; 67:10019-26; PMID:17942936; http:// dx. doi. org/10. 1158/0008-5472. CAN-07-2354
22. Waight JD, Hu Q, Miller A, Liu S, Abrams SI. Tumor-derived G-CSF facilitates neoplastic growth through a granulocytic myeloid-derived suppressor cell-dependent mechanism. PLoS One 2011; 6:e27690; PMID:22110722; http://dx. doi. org/10. 1371/journal. pone. 0027690
23. Marigo I, Bosio E, Solito S, Mesa C, Fernandez A, Dolcetti L, Ugel S, Sonda N, Bicciato S, Falisi E et al. Tumor-induced tolerance and immune suppression depend on the C/EBPbeta transcription factor. Immunity 2010; 32:790-802; PMID:20605485; http://dx. doi. org/ 10. 1016/j. immuni. 2010. 05. 010
24. Lechner MG, Liebertz DJ, Epstein AL. Characterization of cytokineinduced myeloid-derived suppressor cells from normal human peripheral blood mononuclear cells. J Immunol 2010; 185:2273-84; PMID:20644162; http://dx. doi. org/10. 4049/jimmunol. 1000901
25. Corzo CA, Cotter MJ, Cheng P, Cheng F, Kusmartsev S, Sotomayor E, Padhya T, McCaffrey TV, McCaffrey JC, Gabrilovich DI. Mechanism regulating reactive oxygen species in tumor-induced myeloid-derived suppressor cells. J Immunol 2009; 182:5693-701; PMID:19380816; http://dx. doi. org/10. 4049/jimmunol. 0900092
26. Yang R, Cai Z, Zhang Y, Yutzy WHT, Roby KF, Roden RB. CD80 in immune suppression by mouse ovarian carcinoma-associated Gr-1+CD11b+ myeloid cells. Cancer Res 2006; 66:6807-15; PMID:16818658; http://dx. doi. org/10. 1158/0008-5472. CAN-05-3755
27. Nagaraj S, Nelson A, Youn JI, Cheng P, Quiceno D, Gabrilovich DI. Antigen-specific CD4(+) T cells regulate function of myeloid-derived suppressor cells in cancer via retrograde MHC class II signaling. Cancer Res 2012; 72:928-38; PMID:22237629; http://dx. doi. org/10. 1158/ 0008-5472. CAN-11-2863
28. Huang B, Pan PY, Li Q, Sato AI, Levy DE, Bromberg J, Divino CM, Chen SH. Gr-1+CD115+ immature myeloid suppressor cells mediate the development of tumor-induced T regulatory cells and T-cell anergy in tumor-bearing host. Cancer Res 2006; 66:1123-31; PMID:16424049; http://dx. doi. org/10. 1158/0008-5472. CAN-05-1299
29. Pan PY, Ma G, Weber KJ, Ozao-Choy J, Wang G, Yin B, Divino CM, Chen SH. Immune stimulatory receptor CD40 is required for T-cell suppression and T regulatory cell activation mediated by myeloidderived suppressor cells in cancer. Cancer Res 2010; 70:99-108; PMID:19996287; http://dx. doi. org/10. 1158/0008-5472. CAN-09-1882
30. Turnquist HR, Zhao Z, Rosborough BR, Liu Q, Castellaneta A, Isse K, Wang Z, Lang M, Stolz DB, Zheng XX et al. IL-33 expands suppressive CD11b+ Gr-1(int) and regulatory T cells, including ST2L+ Foxp3+ cells, and mediates regulatory T cell-dependent promotion of cardiac allograft survival. J Immunol 2011; 187:4598-610; PMID:21949025; http://dx. doi. org/10. 4049/jimmunol. 1100519
31. Kurowska-Stolarska M, Stolarski B, Kewin P, Murphy G, Corrigan CJ, Ying S, Pitman N, Mirchandani A, Rana B, van Rooijen N et al. IL-33 amplifies the polarization of alternatively activated macrophages that contribute to airway inflammation. J Immunol 2009; 183:6469-77; PMID:19841166; http://dx. doi. org/10. 4049/jimmunol. 0901575
32. Mizukami Y, Kono K, Kawaguchi Y, Akaike H, Kamimura K, Sugai H, Fujii H. CCL17 and CCL22 chemokines within tumor microenvironment are related to accumulation of Foxp3+ regulatory T cells in gastric cancer. Int J Cancer 2008; 122:2286-93; PMID:18224687; http:// dx. doi. org/10. 1002/ijc. 23392
33. Kusmartsev SA, Li Y, Chen SH. Gr-1+ myeloid cells derived from tumor-bearing mice inhibit primary T cell activation induced through CD3/CD28 costimulation. J Immunol 2000; 165:779-85; PMID:10878351; http://dx. doi. org/ji_v165n2p779
34. Youn JI, Nagaraj S, Collazo M, Gabrilovich DI. Subsets of myeloidderived suppressor cells in tumor-bearing mice. J Immunol 2008; 181:5791-802; PMID:18832739; http://dx. doi. org/10. 4049/ jimmunol. 181. 8. 5791
35. Zhu Y, Hu C, Li X, Shao B, Sun H, Zhao H, Li Y. Suppressive effects of aluminum trichloride on the T lymphocyte immune function of rats. Food Chem Toxicol 2012; 50:532-5; PMID:22198605; http://dx. doi. org/10. 1016/j. fct. 2011. 12. 007
36. Zhao X, Rong L, Zhao X, Li X, Liu X, Deng J, Wu H, Xu X, Erben U, Wu P et al. TNF signaling drives myeloid-derived suppressor cell accumulation. J Clin Invest 2012; 122:4094-104; PMID:23064360; http://dx. doi. org/10. 1172/JCI64115
37. Morales JK, Kmieciak M, Knutson KL, Bear HD, Manjili MH. GMCSF is one of the main breast tumor-derived soluble factors involved in the differentiation of CD11b-Gr1-bone marrow progenitor cells into myeloid-derived suppressor cells. Breast Cancer Res Treat 2010; 123:39-49; PMID:19898981; http://dx. doi. org/10. 1007/s10549-009-0622-8
38. Serafini P, Carbley R, Noonan KA, Tan G, Bronte V, Borrello I. Highdose granulocyte-macrophage colony-stimulating factor-producing vaccines impair the immune response through the recruitment of myeloid suppressor cells. Cancer Res 2004; 64:6337-43; PMID:15342423; http:// dx. doi. org/10. 1158/0008-5472. CAN-04-0757
39. Van Ginderachter JA, Beschin A, De Baetselier P, Raes G. Myeloid-derived suppressor cells in parasitic infections. Eur J Immunol 2010; 40:2976-85; PMID:21061431; http://dx. doi. org/10. 1002/ eji. 201040911
40. Gao K, Li X, Zhang L, Bai L, Dong W, Shi G, Xia X, Wu L. Transgenic expression of IL-33 activates CD8(+) T cells and NK cells and inhibits tumor growth and metastasis in mice. Cancer Lett 2013; 335:463-71; PMID:23499895; http://dx. doi. org/10. 1016/j. canlet. 2013. 03. 002
41. Jovanovic IP, Pejnovic NN, Radosavljevic GD, Pantic JM, Milovanovic MZ, Arsenijevic NN, Lukic ML. Interleukin-33/ST2 axis promotes breast cancer growth and metastases by facilitating intratumoral accumulation of immunosuppressive and innate lymphoid cells. Int J Cancer 2014; 134:1669-82; PMID:24105680; http://dx. doi. org/10. 1002/ ijc. 28481
42. Oboki K, Ohno T, Kajiwara N, Arae K, Morita H, Ishii A, Nambu A, Abe T, Kiyonari H, Matsumoto K et al. IL-33 is a crucial amplifier of innate rather than acquired immunity. Proc Natl Acad Sci U S A 2010; 107:18581-6; PMID:20937871; http://dx. doi. org/10. 1073/ pnas. 1003059107
43. Yang L, DeBusk LM, Fukuda K, Fingleton B, Green-Jarvis B, Shyr Y, Matrisian LM, Carbone DP, Lin PC. Expansion of myeloid immune suppressor Gr+CD11b+ cells in tumor-bearing host directly promotes tumor angiogenesis. Cancer Cell 2004; 6:409-21; PMID:15488763; http://dx. doi. org/S1535610804002703
44. Sun P, Ben Q, Tu S, Dong W, Qi X, Wu Y. Serum interleukin-33 levels in patients with gastric cancer. Dig Dis Sci 2011; 56:3596-601; PMID:21643739; http://dx. doi. org/10. 1007/s10620-011-1760-5
45. Ochando JC, Chen SH. Myeloid-derived suppressor cells in transplantation and cancer. Immunol Res 2012; 54:275-85; PMID:22535241; http://dx. doi. org/10. 1007/s12026-012-8335-1
46. Natarajan S, Thomson AW. Tolerogenic dendritic cells and myeloid-derived suppressor cells: potential for regulation and therapy of liver auto-and alloimmunity. Immunobiology 2010; 215:698-703; PMID:20605054; http://dx. doi. org/10. 1016/j. imbio. 2010. 05. 024